Mesenchymal stem cells derived extracellular vesicles ameliorate ovarian aging through inhibiting LGALS3BP/NF-κB induced inflammation.

Shenghui Zhang, Mengyuan Chang, Yajing Chang, Hui Chang, Ying Pan, Xin Zhao, Yanli Liu, Juntang Lin

Department of Clinical Research and Translational Medicine, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. · pubmed

Paper

Abstract

Ovarian aging can lead to early menopause, infertility, and even premature senility in female patients, seriously impairing the quality of life. Unfortunatly, it is still lack of effective protection strategies against ovarian aging. It has been emergingly recognized that mesenchymal stem cells (MSCs) play a pivotal role in the maintenance of organ and tissue homeostasis and extracellular vesicles (EVs) have been identified as significant contributors to the paracrine action of MSCs. Human umbilical cord derived MSCs (UCMSCs) are distinguished by their superior self-renewal potential, minimal immunogenicity, and plentiful supply, rendering them an excellent candidate for EV-based therapeutic transplantation. However, whether UCMSC-EVs improve ovarian aging though regulating inflammation is still uncertain.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that mesenchymal stem cell-derived extracellular vesicles can ameliorate ovarian aging by inhibiting inflammation. This research is relevant as it explores a potential therapeutic approach to address the underlying mechanisms of ovarian aging, which is a significant aspect of female reproductive aging and longevity.

Author of this paper? Send a correction.